This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MannKind, Vical, GTx: Investors Predict Pivotal Clinical Trial Results


GTx is conducting two phase III studies of enobosarm, a selective androgen receptor modulator (SARM) in lung-cancer related muscle wasting. The company's official guidance is to report results in the third quarter but the data are expected to be announced in August.

The survey says: The enobosarm studies will fail, with 39 percent of respondents predicting negative results. Almost the same number of people -- 38 percent -- had no opinion on the outcome of the studies; while only 24 percent predicted positive results. I predict failure for enobosarm's clinical trials, in line with a recent , bearish column about the drug and its previously conducted phase II study.

Here's the pie chart:

My panel of 12 professional healthcare investors are equally unimpressed with GTx and enobosarm. Seventy-five percent predicted negative results versus 17 percent predicting a positive outcome. One investor chose not to respond.

Here's a look at GTx's stock chart for the past six months: GTXI Chart GTXI data by YCharts

GTx's short interest is relatively modest at just over 3 million shares.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MNKD $2.14 6.70%
VICL $0.49 -8.20%
GTXI $0.96 3.23%
TSLA $236.54 2.70%
YHOO $33.54 -0.80%


Chart of I:DJI
DOW 17,820.24 +100.32 0.57%
S&P 500 2,092.06 +11.65 0.56%
NASDAQ 5,131.4460 +22.78 0.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs